Chartsonlygoup's future update (it'll live): tomwong.xyz/stock-status/

What is ALXN's Total Shareholders Equity?

  Alexion Pharmaceuticals Inc ( ALXN ) |
1995 - 2021 (27 years)

Total Shareholders Equity is 
$45.3B (1Y +4.5% )

ALXN Stock Price & Total Shareholders Equity

Total Shareholders Equity for ALXN competitors.
CELG GILD REGN VRTX BIIB AGIO RARE IONS QGEN XON
Note: Stonk = Stock. Both words are used interchangeably. 🙂

Historical (All-Time) Stats for Total Shareholders Equity

chevron_right 2021 $11.7B +3065x
( +34.6% / year avg)
chevron_left 1995 $3.8M
vertical_align_top Peak $44.6B +11731x
vertical_align_bottom Bottom $3.8M
arrow_drop_up # Up Years 20 20 of 27
years up.
arrow_drop_down # Down Years 7
Up Years = Positive (0%+) YoY change
Down Years = Zero or Negative (0% or less) YoY change

Key Points (Stonk Price Comparison)

  • ALXN's stock price has rallied +4,601% from $2.31 in 1995 , or +0.01x the rate relative to it's total shareholders equity over the same period.
  • If ALXN grows it's stock at the same rate as it's total shareholders equity (+34.6%/year) , it's stock price will grow +1,951% and hit $2122.07 over the next 10 years.
  • ALXN's stock price has gone up 0 of the 20 years (0%) it's total shareholders equity were also up.
  • ALXN Historical Total Shareholders Equity Table
    in $ million
    Year Total Shareholders Equity YoY % Change Stock Price YoY % Change (Stock Price)
    4/1/2021 $11,651 -73.9% - -
    4/1/2020 $44,585 13.2% - -
    4/1/2019 $39,402 9.6% - -
    4/1/2018 $35,942 1.6% - -
    4/1/2017 $35,369 44.2% - -
    4/1/2016 $24,520 3.8% - -
    4/1/2015 $23,624 113.1% - -
    4/1/2014 $11,087 28.5% - -
    4/1/2013 $8,627 44.5% - -
    4/1/2012 $5,969 58.3% - -
    4/1/2011 $3,770 24.2% - -
    4/1/2010 $3,034 127.3% - -
    4/1/2009 $1,335 161.8% - -
    4/1/2008 $510 20.7% - -
    4/1/2007 $422 63.1% - -
    4/1/2006 $259 -34.9% - -
    4/1/2005 $397 -29.5% - -
    4/1/2004 $564 -0.8% - -
    4/1/2003 $569 -33.6% - -
    4/1/2002 $856 -19.6% - -
    4/1/2001 $1,065 285.4% - -
    4/1/2000 $276 112.5% - -
    4/1/1999 $130 -15.5% - -
    4/1/1998 $154 74.4% - -
    4/1/1997 $88 53.6% - -
    4/1/1996 $57 1413.2% - -
    4/1/1995 $3 - - -

  • About
    Industry: Biotechnology
    Sector: Healthcare
    Country: US
    IPO Date: 2/1/1996
    Stonk Exchange: NASDAQ
    • Alexion Pharmaceuticals, Inc
    • is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.
    • The company is headquartered in Boston, Massachusetts and currently employs 2,656 full-time employees.
    • The firm is focused on the development and commercialization of therapeutic products.
    • The firm's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).
    • The firm's clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
    • Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS).
    • PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system.
    • Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP).
    • Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D).
    • The company is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.

  • Shareholders equity (also known as Stockholders Equity) represents either the source of a company's assets, the owners' residual claim of a company's assets after its liabilities have been paid, or the company's total book value. Total stockholders' equity represents how much a company would have left over in assets if the company went out of business immediately.

    For more detailed definitions, please see Investopedia.